Insider · CIK 0001762611

Aker Christopher Ray

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001762611

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−7,000 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−488K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−363K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−70K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−394K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−45K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.U Disposition from Tender	Sr. VP & General Counsel	UDisposition from Tender	−60.8K sh	—	—	83,125
2025-06-25	Regulus Therapeutics Inc.D Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−83.1K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−2,500 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−750 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−33.5K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−21K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Sr. VP & General Counsel	DDisposition to Issuer	−48K sh	—	—	0
2025-01-30	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+488K sh	—	—	487,500
2025-01-14	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−5,088 sh	$1.26	−$6,427.162	49,546
2025-01-13	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−38.5K sh	$1.26	−$48.7K	54,634
2025-01-09	Regulus Therapeutics Inc.A Award	Sr. VP & General Counsel	AAward	+17.5K sh	$1.30	+$22.8K	93,181
2025-01-09	Regulus Therapeutics Inc.A Award	Sr. VP & General Counsel	AAward	+66.6K sh	$1.36	+$90.6K	75,681
2024-05-20	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+363K sh	—	—	363,000
2024-01-18	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−5,468 sh	$1.19	−$6,510.201	10,056
2024-01-12	Regulus Therapeutics Inc.A Award	Sr. VP & General Counsel	AAward	+11.3K sh	—	—	15,524
2024-01-12	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+70K sh	—	—	70,000
2023-08-10	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+394K sh	—	—	393,750
2023-01-11	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+45K sh	—	—	45,000
2023-01-11	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+30K sh	—	—	30,000
2022-05-09	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+70K sh	—	—	70,000
2022-01-12	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+480K sh	—	—	480,000
2021-05-17	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−860 sh	$0.89	−$765.4	41,754
2021-02-16	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−828 sh	$1.72	−$1,424.16	42,614
2021-02-04	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+180K sh	—	—	180,000
2020-11-16	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−876 sh	$0.52	−$456.484	25,762
2020-08-14	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−872 sh	$0.60	−$527.56	26,638
2020-05-15	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−909 sh	$0.63	−$569.761	27,510
2020-02-18	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−888 sh	$0.83	−$737.484	28,419
2020-01-22	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+210K sh	—	—	210,000
2020-01-02	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−2,239 sh	$0.97	−$2,164.441	29,307
2019-11-14	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−833 sh	$0.64	−$533.12	31,546
2019-10-10	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+335K sh	—	—	335,000
2019-10-01	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−2,346 sh	$0.68	−$1,601.614	32,379
2019-08-15	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−899 sh	$0.55	−$494.989	34,725
2019-07-01	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−2,225 sh	$1.31	−$2,918.088	35,624
2019-05-15	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−6,950 sh	$1.41	−$9,796.025	59,309
2019-05-14	Regulus Therapeutics Inc.A Award	Sr. VP & General Counsel	AAward	+38.5K sh	—	—	66,259
2019-05-14	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+7,500 sh	—	—	7,500
2019-04-01	Regulus Therapeutics Inc.S Sale	Sr. VP & General Counsel	SSale	−2,710 sh	$0.98	−$2,659.052	6,287
2019-02-05	Regulus Therapeutics Inc.A Award	Sr. VP & General Counsel	AAward	+25K sh	—	—	27,747
2019-02-05	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Sr. VP & General Counsel	AAward	+25K sh	—	—	25,000

Recent filings

Accepted (ET)
Jun 274
Aker Christopher Ray0000950170-25-091019
SEC(opens sec.gov)
Jan 314
Aker Christopher Ray0000950170-25-011849
SEC(opens sec.gov)
Jan 154
Aker Christopher Ray0000950170-25-005882
SEC(opens sec.gov)
Jan 104
Aker Christopher Ray0000950170-25-004270
SEC(opens sec.gov)
May 214
Aker Christopher Ray0000950170-24-062917
SEC(opens sec.gov)
Jan 184
Aker Christopher Ray0001209191-24-001874
SEC(opens sec.gov)

Companies

Regulus Therapeutics Inc.Sr. VP & General Counsel

Address

C/O REGULUS THERAPEUTICS INC. 4224 CAMPUS POINT CT., #210

SAN DIEGO, CA, 92121